Kevin M Fain1, Carlos Castillo-Salgado2, David D Dore3, Jodi B Segal4, Andrew R Zullo5, G Caleb Alexander6. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Electronic address: kfain1@jhu.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Optum Epidemiology, Waltham, MA; Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI. 4. Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Department of Medicine, Johns Hopkins Medicine, Baltimore, MD. 5. Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI. 6. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Department of Medicine, Johns Hopkins Medicine, Baltimore, MD.
Abstract
OBJECTIVE: We quantified transdermal fentanyl prescribing in elderly nursing home residents without prior opioid use or persistent pain, and the association of individual and facility traits with opioid-naïve prescribing. DESIGN: Cross-sectional study. SETTING: Linked Minimum Data Set (MDS) assessments; Online Survey, Certification and Reporting (OSCAR) records; and Medicare Part D claims. PARTICIPANTS: From a cross-section of all long-stay US nursing home residents in 2008 with an MDS assessment and Medicare Part D enrollment, we identified individuals (≥65 years old) who initiated transdermal fentanyl, excluding those with Alzheimer disease, severe cognitive impairment, cancer, or receipt of hospice care. MEASUREMENTS: We used Medicare Part D to select beneficiaries initiating transdermal fentanyl in 2008 and determined whether they were "opioid-naïve," defined as no opioid dispensing during the previous 60 days. We obtained resident and facility characteristics from MDS and OSCAR records and defined persistent pain as moderate-to-severe, daily pain on consecutive MDS assessments at least 90 days apart. We estimated associations of patient and facility attributes and opioid-naïve fentanyl initiation using multilevel mixed effects logistic regression modeling. RESULTS: Among 17,052 residents initiating transdermal fentanyl, 6190 (36.3%) were opioid-naïve and 15,659 (91.8%) did not have persistent pain. In the regression analysis with adjustments, residents who were older (ages ≥95 odds ratio [OR] 1.69, 95% confidence interval [CI] 1.46-1.95) or more cognitively impaired (moderate-to-severe cognitive impairment, OR 1.99, 95% CI 1.73-2.29) were more likely to initiate transdermal fentanyl without prior opioid use. CONCLUSION: Most nursing home residents initiating transdermal fentanyl did not have persistent pain and many were opioid-naïve. Changes in prescribing practices may be necessary to ensure Food and Drug Administration warnings are followed, particularly for vulnerable subgroups, such as the cognitively impaired.
OBJECTIVE: We quantified transdermal fentanyl prescribing in elderly nursing home residents without prior opioid use or persistent pain, and the association of individual and facility traits with opioid-naïve prescribing. DESIGN: Cross-sectional study. SETTING: Linked Minimum Data Set (MDS) assessments; Online Survey, Certification and Reporting (OSCAR) records; and Medicare Part D claims. PARTICIPANTS: From a cross-section of all long-stay US nursing home residents in 2008 with an MDS assessment and Medicare Part D enrollment, we identified individuals (≥65 years old) who initiated transdermal fentanyl, excluding those with Alzheimer disease, severe cognitive impairment, cancer, or receipt of hospice care. MEASUREMENTS: We used Medicare Part D to select beneficiaries initiating transdermal fentanyl in 2008 and determined whether they were "opioid-naïve," defined as no opioid dispensing during the previous 60 days. We obtained resident and facility characteristics from MDS and OSCAR records and defined persistent pain as moderate-to-severe, daily pain on consecutive MDS assessments at least 90 days apart. We estimated associations of patient and facility attributes and opioid-naïve fentanyl initiation using multilevel mixed effects logistic regression modeling. RESULTS: Among 17,052 residents initiating transdermal fentanyl, 6190 (36.3%) were opioid-naïve and 15,659 (91.8%) did not have persistent pain. In the regression analysis with adjustments, residents who were older (ages ≥95 odds ratio [OR] 1.69, 95% confidence interval [CI] 1.46-1.95) or more cognitively impaired (moderate-to-severe cognitive impairment, OR 1.99, 95% CI 1.73-2.29) were more likely to initiate transdermal fentanyl without prior opioid use. CONCLUSION: Most nursing home residents initiating transdermal fentanyl did not have persistent pain and many were opioid-naïve. Changes in prescribing practices may be necessary to ensure Food and Drug Administration warnings are followed, particularly for vulnerable subgroups, such as the cognitively impaired.
Authors: Charlène Cool; Philippe Cestac; Charlotte Laborde; Cécile Lebaudy; Laure Rouch; Benoit Lepage; Bruno Vellas; Philipe de Souto Barreto; Yves Rolland; Maryse Lapeyre-Mestre Journal: J Am Med Dir Assoc Date: 2014-10-03 Impact factor: 4.669
Authors: Vikram R Comondore; P J Devereaux; Qi Zhou; Samuel B Stone; Jason W Busse; Nikila C Ravindran; Karen E Burns; Ted Haines; Bernadette Stringer; Deborah J Cook; Stephen D Walter; Terrence Sullivan; Otavio Berwanger; Mohit Bhandari; Sarfaraz Banglawala; John N Lavis; Brad Petrisor; Holger Schünemann; Katie Walsh; Neera Bhatnagar; Gordon H Guyatt Journal: BMJ Date: 2009-08-04
Authors: Jacob N Hunnicutt; Stavroula A Chrysanthopoulou; Christine M Ulbricht; Anne L Hume; Jennifer Tjia; Kate L Lapane Journal: J Am Geriatr Soc Date: 2017-09-21 Impact factor: 5.562
Authors: Barbara Resnick; Marie Boltz; Elizabeth Galik; Sarah Holmes; Erin Vigne; Steven Fix; Shijun Zhu Journal: Pain Manag Nurs Date: 2019-05-10 Impact factor: 1.929
Authors: Andrew R Zullo; Tingting Zhang; Geetanjoli Banerjee; Yoojin Lee; Kevin W McConeghy; Douglas P Kiel; Lori A Daiello; Vincent Mor; Sarah D Berry Journal: J Am Geriatr Soc Date: 2018-01-16 Impact factor: 5.562
Authors: Jacob N Hunnicutt; Anne L Hume; Christine M Ulbricht; Jennifer Tjia; Kate L Lapane Journal: Pharmacoepidemiol Drug Saf Date: 2018-06-04 Impact factor: 2.890